Exagen (NASDAQ:XGN) Issues Earnings Results

Exagen (NASDAQ:XGN) issued its earnings results on Tuesday. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.07, Zacks reports. Exagen had a negative net margin of 30.36% and a negative return on equity of 92.58%. Exagen updated its Q1 2025 guidance to EPS.

Exagen Stock Performance

XGN stock traded up $0.14 during midday trading on Tuesday, reaching $2.99. 15,385 shares of the company were exchanged, compared to its average volume of 159,331. Exagen has a one year low of $1.30 and a one year high of $6.22. The firm has a market capitalization of $52.73 million, a price-to-earnings ratio of -3.18 and a beta of 1.40. The business has a 50-day moving average price of $3.80 and a two-hundred day moving average price of $3.57. The company has a debt-to-equity ratio of 1.54, a current ratio of 4.05 and a quick ratio of 4.05.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. William Blair reaffirmed an “outperform” rating on shares of Exagen in a research note on Wednesday, November 13th. Canaccord Genuity Group lifted their price objective on shares of Exagen from $5.00 to $7.00 and gave the company a “buy” rating in a report on Friday, January 3rd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $8.00 target price on shares of Exagen in a report on Monday, January 13th.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).